The case for iron chelation and/or antioxidant therapy in Alzheimer's disease

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 526-530

  Malecki, Elise A ^a   Connor, James R ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antioxidants; Chelators; Iron; Metal toxicity

Indexed keywords

4 (3,5 BIS(3 HYDROXYPHENYL) 1,2,4 TRIAZOL 1 YL)BENZOIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DEFERIPRONE; DEFEROXAMINE; ESTROGEN; FERRITIN; GINKGO BILOBA EXTRACT; ICL 670 A; IRON; IRON CHELATING AGENT; N,N BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N DIACETIC ACID; NITROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDOXAL ISONICOTINOYLHYDRAZONE; REACTIVE OXYGEN METABOLITE; SELENIUM; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CARCINOGENICITY; CATALYSIS; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; IRON CHELATION; NEPHROLITHIASIS; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN CROSS LINKING; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; ZINC DEFICIENCY;

EID: 0036660470     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10105     Document Type: Review

References (51)

1. Abeysinghe RD, Greene BT, Haynes R, Willingham MC, Turner J, Planalp RC, Brechbiel MW, Torti FM, Torti SV. 2001. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis 22:1607-1614.
2. Bergeron RJ, Weigand J, Brittenham GM. 1998. HBED: a potential alternative to deferoxamine for iron-chelating therapy. Blood 91:1446-1452.
3. Burdo JR, Connor JR. 2002. Iron transport in the central nervous system. In: Templeton DM, editor. Molecular and cellular iron transport. New York: Dekker. p 487-508.
4. Bush AI. 2000. Metals and neuroscience. Curr Opin Chem Biol 4:184-191.
5. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, Mullen M, 1991. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353:844-846.
6. Cheepsunthorn P, Radov L, Menzies S, Reid J, Connor JR. 2001. Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia 35:53-62.
7. Cheepsunthorn P, Radov LA, Reid J, Connor JR. 2002. Iron mediates gene expression in activated microglia. Manuscript in preparation.
8. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim YS, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
9. Connor JR, Menzies SL, St. Martin S, Fine RE, Mufson EJ. 1992. Altered cellular distribution of transferrin, ferritin, and iron in Alzheimer's disease brains. J Neurosci Res 31:75-83.
10. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. 1995. A quantitative analysis of isoferritins in select regions of aged, Parkinsonian, and Alzheimer's diseased brains. J Neurochem 65:717-724
11. Connor JR. 1997. Evidence for iron mismanagement in the brain in neurological disorders. In: Connor JR, editor. Metals and oxidative damage in neurological disorders. New York: Plenum. p 23-39.
12. Connor JR, Milward EA, Moalem S, Sampietro M, Boyer P, Percy ME, Vergani C, Scott BJ, Chorney M. 2001. Is hemochromatosis a risk factor for Alzheimer's disease? J Alz Dis 3:471-477.
13. Crapper McLachlan DR, Dalton AJ, Kruk TPA, Bell MY, Smith WL, Kalow W, Andrews DF, 1991. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337:1304-1308.
14. Cutler NR, Sramek JJ. 2001. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Prog Neuropsychopharmacol Biol Psychiatry 25:27-57.
15. Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L, Fidani P, Amici A, Helson L. 1992. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 15:319-322.
16. Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, Leveugle B, Kubis N, Hauw JJ, Agid Y, Hirsch EC. 1995. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl Acad Sci 92:9603-9607.
17. Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG. 1990. Ferritin is a component of neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol 81:105-110.
18. Grundman M, Thal LJ. 2000. Treatment of Alzheimer's disease. Neurol Clin 18:807-827.
19. Halliwell B. 1994. Iron, oxidative damage, and chelating agents. In: Bergeron RJ, Brittenham GM, editors. The development of iron chelators for clinical use. Boca Raton, FL: CRC Press. p 33-56.
20. Hider RC, Porter JB, Singh S. 1994. The design of therapeutically useful iron chelators. In: Bergeron RJ, Brittenham GM, editors. The development of iron chelators for clinical use. Boca Raton, FL: CRC Press. p 353-371.
21. Kaneko Y, Kitamoto T, J, T, Yamaguchi K. 1989. Ferritin immunohistochemistry as a marker for microglia. Acta Neuropathol 79:129-136.
22. Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R. 2002. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology 45:19-26.
23. Loske C, Gerdemann A, Schepl W, Wycislo M, Scinzel R, Palm D, Riederer P, Münch G. 2000. Transition metal-mediated glycoxidation accelerates cross-linking of β-amyloid peptide. Eur J Biochem 267:4171-4178.
24. Lue L-F, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD. 2001. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171:29-45.
25. Machlin LJ, Bendich A. 1987. Free radical tissue damage: protective role of antioxidant nutrients. FASEB J 1:441-445.
26. Malecki EA, Devenyi AG, Beard JL, Connor JR. 1999. Existing and emerging mechanisms for iron and manganese transport to the brain. J Neurosci Res 56:113-122.
27. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE. 1993. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 61:1171-1174.
28. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, Evans DA. 1998. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Dis 12:121-126.
29. Murrell J, Farlow M, Ghetti B. 1991. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254:97-99.
30. Nick HP, Lattmann R, Alberti D. 2001. ICL670A: in vitro and in vivo properties of a potent iron chelator [abstract O71]. BioIron Meeting, Cairns, Australia.
31. Perry G, Kamiuski MA, Nunomura A, Raina AK, Smith MA. 2000. What oxidative stress tells us about therapeutic targets for Alzheimer's disease. Curr Opin CPNS Invest Drugs 2:423-426.
32. Piñero DJ, Hu J, Connor JR. 2000. Alterations in the interaction between iron regulatory proteins and their responsive element in normal and Alzheimer's diseased brains. Cell Mol Biol 46:761-776.
33. Pippard MJ. 1994. Iron chelation therapy in the treatment of iron overload. In: Bergeron RJ, Brittenham GM, editors. The development of iron chelators for clinical use. Boca Raton, FL: CRC Press. p 57-74.
34. Prasad KN, Hovland AR, Cole WC, Prasad KC, Nahreini P, Edwards-Prasad J, Andreatta CP. 2000. Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin Neuropharmacol 23:2-13.
35. Regland B, Lehman W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjögren M, Wallin A, Xilinas ME, Gottfries C-G. 2001. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 12:408-414.
36. Richardson DR, Mouralian C, Ponka P, Becker E. 2001. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta 1536:133-140.
37. Ringel F, Schmid-Elsaesser R. 2001. Antioxidants for CNS ischaemia and trauma. Expert Opin Ther Patents 11:987-997.
38. Robb S, Robb-Gaspers L, Scaduto RJ, Thomas A, Connor J. 1999. Influence of calcium and iron on cell death and mitochondrial function in oxidatively stressed astrocytes. J Neurosci Res 55:674-686.
39. Saleppico S, Mazzolla R, Boelaert JR, Puliti M, Barluzzi R, Bistoni F, Blasi E. 1996. Iron regulates microglial cell-mediated secretory and effector functions. Cell Immunol 170:251-259.
40. Saleppico S, Boelaert JR, Sale FO, Mazzolla R, Morucci P, Bistoni F, Blasi E. 1999. Differential effects of iron load on basal and interferon-gamma plus lipopolysaccharide enhance anticryptococcal activity by the murine microglial cell line BV-2. J. Neuroimmunology 93:102-107.
41. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ, 1997. A controlled trial of selegilene, alpha-tocopherol, or both as treatment for Alzheimer's disease. New Engl J Med 336:1216-1222.
42. Smith MA, Harris PLR, Sayre LM, Perry G. 1997. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94:9866-9868.
43. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. 2000. Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 1502:139-144.
44. Tateishi J. 2000. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 20 (suppl):S20-S24.
45. Templeton DM. 1995. Therapeutic use of chelating agents in iron overload. In: Goyer RA, Cherian MG, editors. Toxicology of metals: biochemical aspects. Heidelberg: Springer-Verlag. p 305-331.
46. Thompson K, Menzies SL, Wood T, Boyer PJ, Beard JL, Torti S, Torti F, Connor JR. 2001a. Perturbations of H-ferritin in mice results in alterations in brain iron homeostasis. FASEB J 15:A733.
47. Thompson KJ, Shoham S, Connor JR. 2001b. Iron and neurodegenerative disorders. Brain Res Bull 55:155-164.
48. Uversky VN, Li J, Fink AL. 2001. Metal-triggered structural transformations, aggregation, and fibrillation of human alphasynuclein. J Biol Chem 276:44284-44296.
49. Weinberg ED. 1994. Iron withholding: the natural defense system and its modification by pharmacologic agents. In: Bergeron RJ, Brittenham GM, editors. The development of iron chelators for clinical use. Boca Raton, FL: CRC Press. p 97-109.
50. Weiss G, Werner-Felmayer G, Werner ER, Grunewald K, Watchter H, Hentze MW. 1994. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 180:969-976.
51. Yao Z, Drieu K, Papadopoulos V. 2001. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res 889:181-190.